Controversies in the treatment of atherosclerosis include uncertainty about the benefits of fibric acid derivatives, whether inhibition of cholesterol ester transfer protein is helpful or harmful, and about the benefits of statins in patients with renal failure. Key studies in 2010 contributed to the resolution of these long-standing controversies.
